Industry
Biotechnology
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Loading...
Open
44.40
Mkt cap
3.3B
Volume
546K
High
44.63
P/E Ratio
-332.46
52-wk high
46.00
Low
42.84
Div yield
N/A
52-wk low
18.61
Portfolio Pulse from
December 05, 2024 | 9:30 pm
Portfolio Pulse from
November 07, 2024 | 5:00 pm
Portfolio Pulse from
November 07, 2024 | 4:00 am
Portfolio Pulse from
November 07, 2024 | 12:30 am
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 2:59 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 1:03 pm
Portfolio Pulse from Benzinga Insights
October 10, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 3:46 pm
Portfolio Pulse from Benzinga Newsdesk
October 02, 2024 | 12:23 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.